Peter Bains to replace Jonathan Hunt as CEO of Syngene
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Subscribe To Our Newsletter & Stay Updated